LSI’s Post

[Clinical Trials] NeuroSense Therapeutics reports phase 2b trial results of PrimeC in ALS indicating reduced risk of disease complications and slower progression https://lnkd.in/gntGVcH8 CymaBay Therapeutics' phase 3 trial of seladelpar yields significant efficacy in primary biliary cholangitis endpoints https://lnkd.in/gu_sAxbc SynAct Pharma reports phase 2b trial of AP1189 reveals efficacy endpoints met in Rheumatoid Arthritis patients with elevated baseline CRP https://lnkd.in/g4KMythz [Deals] Immunocore Holdings and 브리스톨마이어스스큅 Collaborate on phase 3 Clinical Trial for IMC-F106C in Cutaneous Melanoma Treatment https://lnkd.in/gUchXuzB

Immune-Onc Therapeutics and Roche Partner to Assess IO-108 for the Treatment of Advanced Hepatocellular Carcinoma #roche #immuneonctherapeutics #io108 #hepatocellularcarcinoma #pharma #collaboration #partnership #agreement #development #pii #safety #efficacy #clinicaltrials #tecentriq #avastin #morpheusliver #program

Big news for the treatment of pancreatic cancer this week. On Tuesday, the FDA approved the use of the first liposomal-based frontline treatment for metastatic pancreatic adenocarcinoma (mPDAC). The approval was based on the results of phase III trials consisting of 770 patients. The therapeutic agent, called Onivyde was approved for use in combination with three chemotherapeutic drugs. A differentiating factor of Onivyde is the formulation, which relies on liposomes that can be internalized by cells to deliver “slow release” payloads enabling safer dosing and longer therapeutic effect after each treatment. Compared to the current standard of care, which has not changed in over a decade, the treatment regimen increased overall patient survival by 17% and improved progression free survival by 31%. Sources: Biospace, FiercePharma, Ipsen ---------- For weekly biotech and pharma news highlights, delivered straight to your inbox, subscribe to the Trulitica newsletter👇 https://lnkd.in/gwuQyVfg #biotech #pharma #oncology

1. PharmAust has rebranded as Neurizon Therapeutics, seeing a share price increase of approximately 90% year-to-date. 2. The company is advancing its lead drug, monepantel, now called NUZ-001, targeting neurodegenerative diseases, starting with ALS. 3. A Phase 2/3 clinical trial for NUZ-001 is set to begin in Q1 2025 as part of the HEALEY ALS Platform Trial. 4. NUZ-001 has received orphan drug designation from the FDA, providing benefits such as tax credits and market exclusivity. 5. The drug inhibits the mTOR pathway to help clear misfolded proteins in ALS, potentially slowing disease progression. 6. Early results from trials show NUZ-001 may reduce ALS symptom decline by 39% and improve patient survival rates significantly. 7. The market for ALS therapies exceeds $2 billion annually, with a high demand for effective treatments due to the lack of current cures. 8. Neurizon's strategy focuses on improving patient access, partnering with neurologists, and exploring the drug's potential for other neurodegenerative diseases.

Don't miss the #VT1021 update from Vigeo Therapeutics COO Dr. Jing Watnick at the Fifth Annual Glioblastoma Drug Development Summit in Boston MA this week. Dr. Watnick will be speaking during the afternoon session on 28 March on The #VT1021 Ph1/2 clinical program in #glioblastoma as well the potential future use of #VT1021 in Neuro-inflammatory diseases #GBM #Glioblastoma #NeuroinflammatoryDiseases #VT1021

Join us for our upcoming webinar where our expert speakers will delve into the latest data from ASCO and recent conferences, highlighting opportunities to escalate treatment for high-risk populations across tumor types and treatment settings. Key data includes insights on breast cancer, gastroesophageal cancer, bladder cancer, head & neck cancer, and colorectal cancer. Highlights you can expect: - In the MonarchE study, ctDNA+ in the adjuvant setting was highly prognostic of clinical outcomes in breast cancer. - A multi-institutional analysis revealed that ctDNA-positivity impacted the care plan of 91% of patients analyzed. - In gastroesophageal cancer, ctDNA results in the peri-operative setting correlated with long-term outcomes. - Patients with bladder cancer who remained MRD-negative on serial testing showed exceptional outcomes. - MRD-positive Signatera patients in head & neck cancer had inferior PFS post-treatment. - Results from the MD Anderson INTERCEPT program showed promising outcomes in colorectal cancer treatment. Don't miss out on the topline results expected later this year from the Phase III ALTAIR trial. Save your spot and register!

https://lnkd.in/ggEsXYW3 Key Insights: • Tagrisso with chemo offers a 38% reduction in the risk of disease progression or death compared to standard treatment, providing a significant advantage for patients • The combination offers an 8.8-month increase in median progression-free survival, potentially extending the time patients live without their cancer worsening. This translates to a 53% improvement in PFS compared to Tagrisso alone Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #astrazeneca #anticancer #treatment #partners #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress "The first clinical data for HMB-001 in Glanzmann suggest that the demonstrated mechanism is suitable as a new prophylactic treatment for people with neglected blood clotting disorders who face severe, potentially life-threatening bleeds every day," said Joe Vogel, Senior Director and Program Lead for HMB-001 at Hemab. "With Phase 2 already underway, we are committed to advancing clinical evaluation of HMB-001 toward bringing life-changing preventative treatments to improve patients' quality of life." VINODKUMAR VORA Nimish Dudhatra https://lnkd.in/d8dfjXwh

🚀 Are you aware that a diabetes medication is now enhancing the treatment of lung cancer? The pharmaceutical landscape is undergoing remarkable changes right before our eyes. 💡 A drug designed for diabetic neuropathy is notably increasing the efficacy of chemotherapy in lung cancer patients. This breakthrough has the potential to redefine cancer treatment methodologies. Simultaneously, researchers have introduced a new compound aimed at combating opioid overdoses, particularly those involving fentanyl, highlighting the rapid advancements in emergency medical care. 🔬 In another pioneering study, researchers have re-engineered cancerous tumors to self-destruct, focusing on drug-resistant cells. This represents a significant development in cancer therapeutics. Moreover, impressive strides continue to be made: antimicrobial peptides are now effectively slowing down antibiotic resistance, and visible light synthesis is providing new pharmaceutical building blocks. 🌐 The growing role of social media in the pharmaceutical industry ensures the timely dissemination of crucial information, thereby empowering healthcare decisions. Which recent pharmaceutical advancements have captured your interest? Let us discuss. #PharmaceuticalRevolution #CancerTreatment #InnovativeResearch #EmergencyCare #DrugDiscovery #HealthcareAdvancements #CancerTherapeutics #AntibioticResistance #PharmaceuticalBuildingBlock